Supplement Bioavailability Explained: Why High Absorption Doesn't Guarantee Results
Bioavailability is one of the most commonly cited metrics in the supplement industry. Brands advertise absorption rates like a scorecard — the higher the number, the better the product. But the science tells a more nuanced story. Getting a compound into your bloodstream is only the first step in a much longer chain, and it may not even be the most important one.
In this article, we look at what bioavailability actually measures, why blood levels alone don't predict whether a supplement will work, and what the research suggests you should pay attention to instead. We'll examine real examples where high absorption hasn't translated to clear benefits — and cases where low bioavailability hasn't prevented them.
Supplement Bioavailability · At a Glance
Definition
The fraction of an ingested dose that reaches your bloodstream in its active form
Intravenous injection = 100% bioavailability by definition
Key Insight
Blood levels measure transit, not destination — a compound must still reach its target tissue and trigger a biological response
Brain Challenge
The blood-brain barrier blocks more than 98% of small-molecule drugs from entering the brain
What Matters
Tissue targeting, timing, receptor binding strength, and measurable functional outcomes
Table of Contents
- What Bioavailability Actually Measures
- Why Blood Levels Aren't the Whole Story
- The Curcumin Paradox: More Absorption, Mixed Results
- The Blueberry Paradox: Low Absorption, Real Benefits
- The Blood-Brain Barrier Challenge
- What Actually Predicts Whether a Supplement Works
- How We Think About Formulation
- Frequently Asked Questions
- References
What Bioavailability Actually Measures
In pharmacology, bioavailability refers to the fraction of an administered dose that reaches your systemic circulation — your blood — in its active form. An intravenous injection has 100% bioavailability by definition, because the entire dose enters the bloodstream directly. When you take something by mouth, the number is almost always lower.
An oral supplement faces a gauntlet of biological obstacles before it reaches your blood. Stomach acid may degrade it. Enzymes in the gut wall may metabolise it. The liver gets first pass at filtering it before it enters general circulation. Whatever fraction survives all of these steps is the bioavailability.
Analogy
Think of your bloodstream as a bank account. An intravenous injection is a direct deposit — if £100 is sent, exactly £100 arrives. An oral supplement is more like mailing a cheque through a chain of intermediaries, each of whom may take a cut. The amount that finally lands in the account is the bioavailability.
This is a useful metric, but it only tells you about one stage of the journey. The fact that a compound reaches your blood doesn't tell you whether it reaches the tissue where it's needed, whether it arrives at the right time, or whether it does anything useful once it gets there.
Bioavailability measures how much of an oral dose reaches the bloodstream. It's an important pharmacokinetic property, but it describes a transit point — not the final destination.
Why Blood Levels Aren't the Whole Story
If you're taking a supplement to support brain function, your blood is a highway, not the destination. A compound needs to leave the bloodstream, cross into the right tissue, bind to the right biological target — a receptor, an enzyme, a membrane — and trigger a response that actually matters for the outcome you care about.
Each of these steps introduces its own set of variables. A compound might be highly bioavailable but poorly distributed to the target tissue. It might reach the tissue but at concentrations too low to have a meaningful effect. It might bind weakly to its target, or it might bind strongly but not at the right time in the biological cycle.
Analogy
Imagine ordering a package online. Bioavailability tells you the parcel was delivered to your city's sorting office. But that doesn't mean it reached your front door, was opened, or contained something useful. The sorting office is a necessary waypoint, but it's not the measure of success.
This distinction matters because the supplement industry often uses bioavailability as a proxy for efficacy. The implicit argument is: more in the blood means more effect. But as we'll see with two contrasting examples — curcumin and blueberry anthocyanins — the relationship between absorption and outcomes is not that straightforward.
Getting into the bloodstream is necessary but not sufficient. A supplement's value depends on whether the active compound reaches its biological target and produces a measurable functional change.
The Curcumin Paradox: More Absorption, Mixed Results
Curcumin, the primary bioactive compound in turmeric, is one of the most studied natural substances in the world. Standard curcumin has notoriously poor oral bioavailability — most of it is metabolised before it reaches circulation. This has led to a wave of enhanced formulations designed to dramatically increase blood levels: nanoparticles, liposomes, piperine combinations, and phospholipid complexes.
These formulations have been remarkably successful at solving the absorption problem. Some can increase plasma curcumin levels by 20- to 100-fold compared to standard curcumin powder. But the key question is: has this translated into proportionally better clinical outcomes?
A 2019 review of curcumin's biological, pharmaceutical, and analytical properties found that despite numerous formulations dramatically improving bioavailability, clinical evidence remains mixed — poor aqueous solubility and rapid metabolism continue to limit therapeutic usage, and the sheer variety of formulations makes it difficult to compare results across studies.
More recently, a 2025 meta-analysis pooled data from 18 randomised controlled trials examining curcumin combined with piperine (a black pepper extract that inhibits liver metabolism). The results were telling: significant reductions in some inflammatory markers (AST and IL-6) but no significant changes in others (CRP, TNF-α). Benefits were most pronounced in overweight participants and with supplementation lasting 12 weeks or longer — suggesting the effects are population-specific rather than universal.
The pattern here is instructive. Enhanced bioavailability has successfully increased the amount of curcumin in the blood. But the clinical picture remains complicated — effects appear to be population-specific, dose-dependent, and highly variable. This doesn't mean curcumin is ineffective, but it demonstrates that solving the absorption problem doesn't automatically solve the efficacy problem.
Curcumin illustrates a critical gap: dramatically improving bioavailability has not consistently produced proportionally stronger clinical outcomes. Absorption is a necessary step, but it appears to be only one variable in a more complex equation.
The Blueberry Paradox: Low Absorption, Real Benefits
If the curcumin story suggests that high bioavailability doesn't guarantee results, blueberry anthocyanins suggest the opposite problem: low bioavailability doesn't necessarily prevent them.
Anthocyanins — the compounds that give blueberries their deep colour — have very low systemic bioavailability. Only a small fraction of ingested anthocyanins appear in the blood in their original form. By traditional bioavailability logic, they shouldn't do much. But the clinical evidence tells a different story.
Key Study
Who: 61 healthy older adults, aged 65–80 years
Dose: 26 g freeze-dried wild blueberry powder daily (302 mg anthocyanins) for 12 weeks
Measured: Endothelial function (flow-mediated dilation), cognitive function, blood pressure, cerebral blood flow
Findings: Significant improvement in endothelial function, reduction in 24-hour ambulatory systolic blood pressure, enhanced immediate recall on verbal learning tasks, and better accuracy on task-switching. Despite these outcomes, urinary metabolite analysis confirmed the expected low systemic anthocyanin levels.
Limitations: Modest sample size; 12-week duration; healthy population at baseline; no changes detected in cerebral blood flow or gut microbiota
Wood et al., 2023 · PubMed
These findings aren't isolated. A separate trial in overweight middle-aged adults with insulin resistance and subjective cognitive decline found that 12 weeks of daily blueberry supplementation improved lexical access and memory interference performance, reduced memory encoding difficulty in daily activities, and corrected peripheral hyperinsulinemia — despite the same expected low anthocyanin bioavailability. The study was small and the population specific, but it points in the same direction.
How do compounds with such poor systemic bioavailability produce measurable cognitive and cardiovascular benefits? Several mechanisms have been proposed. Anthocyanins may exert local effects in the gut before being absorbed. Their metabolites — which are different compounds from the parent anthocyanins — may be the actual active agents. And the standard bioavailability measurement, which looks for the original compound in blood, may simply not capture what's happening biologically.
Blueberry anthocyanins challenge the assumption that bioavailability predicts efficacy. Despite very low systemic absorption, randomised controlled trials have found measurable improvements in vascular function, blood pressure, and cognitive performance in older adults.
The Blood-Brain Barrier Challenge
For supplements targeting brain health, there's an additional obstacle that standard bioavailability metrics don't capture at all: the blood-brain barrier (BBB).
The BBB is one of the most selective biological filters in the human body. It's formed by specialised endothelial cells in brain capillaries that create extremely tight junctions, restricting what can pass from the blood into brain tissue. According to research by Pardridge, the BBB excludes more than 98% of small-molecule drugs and nearly all large-molecule therapeutics from entering the brain.
Analogy
If systemic bioavailability is like getting a parcel to the sorting office, the blood-brain barrier is like a building with its own private security team. Even if the parcel arrives in the city, it still has to pass through a checkpoint that turns away the vast majority of deliveries.
This means that for brain-targeted supplements, there are effectively two bioavailability problems. The first is getting the compound into the blood (oral bioavailability). The second is getting it from the blood into the brain (BBB permeability). A compound can score well on the first metric and fail completely on the second.
This is why, when evaluating ingredients for brain health, it matters whether a compound has demonstrated the ability to cross the BBB — not just whether it reaches the blood. Clinical trials that measure cognitive outcomes are more informative than pharmacokinetic studies that only measure plasma levels.
The blood-brain barrier adds a second layer of selectivity that standard bioavailability measures don't account for. For brain health supplements, the ability to cross this barrier may be more relevant than overall oral absorption.
What Actually Predicts Whether a Supplement Works
If bioavailability alone isn't sufficient to predict outcomes, what should we look for instead? Based on the pharmacological evidence, four factors appear to matter more than raw absorption numbers.
1. Tissue Targeting
Does the active compound reach the specific tissue where it needs to act? For a brain health supplement, this means crossing the blood-brain barrier. For a joint supplement, it means accumulating in cartilage. Blood levels are a prerequisite, but they're not a reliable proxy for tissue concentrations.
2. Timing and Biological Windows
Many biological processes are time-dependent. Neurotransmitter synthesis, membrane repair, and cellular energy production all operate on schedules. A compound that arrives at the right tissue but at the wrong time may have a reduced effect. This is one reason why dosing frequency and timing relative to meals or circadian rhythms can influence outcomes.
3. Receptor Binding and Signal Strength
Once at the target tissue, the compound needs to interact with its biological target strongly enough to produce a response. This is about binding affinity and intrinsic activity — pharmacological properties that have nothing to do with how much was absorbed from the gut.
4. Measurable Functional Outcomes
Ultimately, what matters is whether the supplement produces a change that can be measured and that's relevant to the person taking it. This means looking for clinical trials that report cognitive test scores, reaction times, mood assessments, or physiological measurements — not just blood level curves.
Rather than asking "how bioavailable is this?" consider asking: does it reach the right tissue, at the right time, with enough potency to produce a measurable outcome? Clinical trials measuring functional endpoints are the most reliable guide.
How We Think About Formulation
When developing eudopa™, we chose ingredients based on the framework outlined above — prioritising compounds with evidence of reaching their biological targets and producing measurable outcomes, rather than optimising purely for absorption numbers.
Citicoline: High Bioavailability That Translates
Citicoline (CDP-choline) is one of the clearer success stories in supplement pharmacology. A comprehensive pharmacological review found that oral citicoline is absorbed almost completely, with bioavailability approximately equal to intravenous administration. Once absorbed, its two components — cytidine and choline — cross the blood-brain barrier and are incorporated into neuronal membrane phospholipids. Research has also shown it increases dopamine and norepinephrine levels in the central nervous system, with clinical evidence supporting improvements in cognitive function across multiple patient populations. Most of that clinical evidence comes from post-stroke and dementia cohorts rather than healthy adults, so the optimal dose for cognitive optimisation in healthy people is less well established.
Citicoline is a case where high bioavailability aligns with BBB penetration and demonstrated functional outcomes. The high absorption rate is meaningful here because the compound actually reaches its target — the brain — and has evidence of producing cognitive effects.
Phosphatidylserine: Membrane Integration
Phosphatidylserine (PS) is a phospholipid that makes up a significant portion of neuronal cell membranes. Supplementation with PS has been investigated for its effects on cognitive function and stress response, with clinical trials typically using doses between 100 and 300 mg daily.
A small trial in healthy men found that 42 days of PS supplementation significantly altered frontal brain activity in a pattern associated with a more relaxed cognitive state under stress, though the sample was only 16 participants. A larger and more recent randomised controlled trial in healthy children aged 8–12 found no significant differences in primary cognitive outcomes overall, but did observe improvements in visuospatial memory among children who started with below-median performance — a subgroup finding that suggests PS may be most beneficial for those with room to improve.
The PS evidence is more modest than citicoline's, and we present it honestly. The mechanism is plausible — PS is a genuine component of neuronal membranes, and supplementation may support membrane fluidity and cell signalling. But the clinical evidence is still developing, with effects appearing most clearly in specific subgroups rather than across the board.
Wild Blueberry Anthocyanins: Beyond Bioavailability
As discussed earlier, blueberry anthocyanins have low systemic bioavailability by conventional measurement. We included wild blueberry extract in eudopa™ not because of its absorption profile, but because of its clinical outcomes profile. The randomised controlled trials showing improved vascular function, blood pressure reduction, and cognitive benefits in older adults provided stronger evidence than any bioavailability figure could.
We chose these ingredients based on clinical evidence of reaching their biological targets and producing measurable cognitive and physiological outcomes — not solely on absorption metrics. Each ingredient addresses a different aspect of brain health through a distinct mechanism.
Frequently Asked Questions
What does bioavailability mean in supplements?
Bioavailability is the percentage of an ingested supplement that reaches your bloodstream in its active form. It accounts for losses from stomach acid degradation, gut wall metabolism, and first-pass liver metabolism. A higher percentage means more reaches your blood, but this doesn't necessarily mean more reaches your target tissue or produces a stronger effect.
Is higher bioavailability always better?
Not necessarily. High bioavailability means more of the compound reaches your blood, but the bloodstream is a transit route, not the destination. The compound still needs to reach the right tissue, bind to the right targets, and trigger a meaningful biological response. Curcumin formulations have dramatically increased blood levels without proportionally improving clinical outcomes. Meanwhile, blueberry anthocyanins show measurable benefits despite very low systemic bioavailability.
What is the blood-brain barrier and why does it matter for brain supplements?
The blood-brain barrier is a layer of specialised cells lining the brain's blood vessels that tightly controls what enters brain tissue. Research suggests it blocks more than 98% of small-molecule drugs and nearly all large molecules. For brain health supplements, this means a compound needs to both reach the bloodstream and then pass through this additional filter — two separate challenges that standard bioavailability measures don't distinguish between.
How can I tell if a brain supplement will actually work?
Look for clinical studies that measure cognitive outcomes — not just blood levels or absorption rates. Randomised controlled trials that report improvements in memory, attention, reaction time, or other functional measures provide more useful evidence than pharmacokinetic studies showing high plasma concentrations. Also look for whether the ingredient has demonstrated the ability to cross the blood-brain barrier.
What's more important than bioavailability when choosing a supplement?
Four factors tend to matter more: whether the compound reaches its target tissue (not just the blood), whether it arrives during the right biological window, whether it binds strongly enough to its target to produce a response, and whether clinical trials have shown measurable functional outcomes. Bioavailability is one piece of this puzzle, but it's not the whole picture.
Does citicoline have good bioavailability?
Yes. Research indicates that oral citicoline is absorbed almost completely, with bioavailability approximately equal to intravenous administration. Importantly, citicoline also crosses the blood-brain barrier, which means the high absorption rate translates into brain availability — a combination that not all well-absorbed compounds achieve.
Why do blueberry anthocyanins work despite low bioavailability?
This is an active area of research. Several mechanisms have been proposed: anthocyanins may exert local effects in the gut that influence systemic health through the gut-brain axis; their metabolites (breakdown products) may be the actual active compounds rather than the parent anthocyanins; and the standard blood measurement may not capture what's happening at the tissue level. Whatever the mechanism, randomised controlled trials have consistently shown vascular and cognitive benefits.
References
- Pardridge WM, "The blood-brain barrier: bottleneck in brain drug development," NeuroRx, vol. 2, no. 1, pp. 3-14, 2005. PubMed
- Secades JJ, Lorenzo JL, "Citicoline: pharmacological and clinical review, 2006 update," Methods Find Exp Clin Pharmacol, vol. 28 Suppl B, pp. 1-56, 2006. PubMed
- Kotha RR, Luthria DL, "Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects," Molecules, vol. 24, no. 16, 2019. PubMed
- Karimi M et al., "Effects of Curcuminoids Plus Piperine Co-Supplementation on Liver Enzymes and Inflammation in Adults: A GRADE-Assessed Systematic Review and Meta-Analysis," Food Sci Nutr, vol. 13, no. 7, 2025. PubMed
- Wood E et al., "Wild blueberry (poly)phenols can improve vascular function and cognitive performance in healthy older individuals: a double-blind randomized controlled trial," Am J Clin Nutr, vol. 117, no. 6, pp. 1306-1319, 2023. PubMed
- Krikorian R et al., "Blueberry Supplementation in Midlife for Dementia Risk Reduction," Nutrients, vol. 14, no. 8, 2022. PubMed
- Baumeister J et al., "Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress," Nutr Neurosci, vol. 11, no. 3, pp. 103-110, 2008. PubMed
- Friling M et al., "The cognitive effects of supplementation with sunflower phosphatidyl serine in healthy children aged 8 to 12 years: a randomized controlled trial," Nutr J, vol. 25, no. 1, pp. 3, 2025. PubMed
This article is for informational purposes only and does not constitute medical advice. The research cited reflects current evidence as of February 2026 and may be updated as new studies are published. Consult a qualified healthcare professional before starting any supplement regimen.
Applied brain science. Delivered weekly.
Weekly tips on brain science, habits, and supplements.
No spam. Unsubscribe anytime.
